Dataset Information

Identification of novel inhibitors of the amino acid transporter B⁰ AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes.

ABSTRACT:

Background and purpose

The neutral amino acid transporter B⁰ AT1 (SLC6A19) has recently been identified as a possible target to treat type 2 diabetes and related disorders. B⁰ AT1 mediates the Na⁺ -dependent uptake of all neutral amino acids. For surface expression and catalytic activity, B⁰ AT1 requires coexpression of collectrin (TMEM27). In this study, we established tools to identify and evaluate novel inhibitors of B⁰ AT1.

Experimental approach

A CHO-based cell line was generated, stably expressing collectrin and B⁰ AT1. Using this cell line, a high-throughput screening assay was developed, which uses a fluorescent dye to detect depolarisation of the cell membrane during amino acid uptake via B⁰

SUBMITTER: Cheng Q

PROVIDER: S-EPMC5323516 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Identification of novel inhibitors of the amino acid transporter B⁰ AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes.

Background and purpose

Experimental approach

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Identification of novel inhibitors of the amino acid transporter B0 AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes.

Background and purpose

Experimental approach

OmicsDI is part of the ELIXIR infrastructure

Tweets

Identification of novel inhibitors of the amino acid transporter B⁰ AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes.